T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients

A Randomized, Double-Blind Clinical Trial

Dimitrios Karussis, Hagai Shor, Julia Yachnin, Naama Lanxner, Merav Amiel, Keren Baruch, Yael Keren-Zur, Ofra Haviv, Massimo Filippi, Panayiota Petrou, Shalom Hajag, Urania Vourka-Karussis, Adi Vaknin-Dembinsky, Salim Khoury, Oded Abramsky, Henri Atlan, Irun R. Cohen, Rivka Abulafia-Lapid

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. Aim: To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial. Methodology: Twenty-six patients with relapsing-progressive MS were enrolled in the study (mean age: 39±9.8 years; mean EDSS: 4.4±1.7). T-cell lines reactive to 9 different peptides of the myelin antigens, MBP, MOG and PLP were raised from the patients' peripheral blood. The patients were randomized into two groups: 19 were treated with TCV (four subcutaneous injections of 10-30×106 T-cells, attenuated by irradiation, on days 1, 30, 90 and 180) and 7 patients were treated with sham injections. Twenty-four patients (17 in the TCV group and 7 in the placebo) were eligible for per-protocol analysis. Results: At one year following the inclusion, an increase in the EDSS (+0.50) and an increase in 10-meter walking time (+0.18 sec), were observed in the placebo group; in the TCV group there was a decrease in the EDSS (-0.44; p

Original languageEnglish
Article numbere50478
JournalPLoS One
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 14 2012

Fingerprint

Chronic Progressive Multiple Sclerosis
T-cells
sclerosis
clinical trials
Vaccination
T-lymphocytes
vaccination
Clinical Trials
T-Lymphocytes
myelin sheath
Myelin Sheath
Multiple Sclerosis
placebos
irradiation
Placebos
Irradiation
Controlled Clinical Trials
subcutaneous injection
Subcutaneous Injections
walking

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Karussis, D., Shor, H., Yachnin, J., Lanxner, N., Amiel, M., Baruch, K., ... Abulafia-Lapid, R. (2012). T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial. PLoS One, 7(12), [e50478]. https://doi.org/10.1371/journal.pone.0050478

T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients : A Randomized, Double-Blind Clinical Trial. / Karussis, Dimitrios; Shor, Hagai; Yachnin, Julia; Lanxner, Naama; Amiel, Merav; Baruch, Keren; Keren-Zur, Yael; Haviv, Ofra; Filippi, Massimo; Petrou, Panayiota; Hajag, Shalom; Vourka-Karussis, Urania; Vaknin-Dembinsky, Adi; Khoury, Salim; Abramsky, Oded; Atlan, Henri; Cohen, Irun R.; Abulafia-Lapid, Rivka.

In: PLoS One, Vol. 7, No. 12, e50478, 14.12.2012.

Research output: Contribution to journalArticle

Karussis, D, Shor, H, Yachnin, J, Lanxner, N, Amiel, M, Baruch, K, Keren-Zur, Y, Haviv, O, Filippi, M, Petrou, P, Hajag, S, Vourka-Karussis, U, Vaknin-Dembinsky, A, Khoury, S, Abramsky, O, Atlan, H, Cohen, IR & Abulafia-Lapid, R 2012, 'T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial', PLoS One, vol. 7, no. 12, e50478. https://doi.org/10.1371/journal.pone.0050478
Karussis, Dimitrios ; Shor, Hagai ; Yachnin, Julia ; Lanxner, Naama ; Amiel, Merav ; Baruch, Keren ; Keren-Zur, Yael ; Haviv, Ofra ; Filippi, Massimo ; Petrou, Panayiota ; Hajag, Shalom ; Vourka-Karussis, Urania ; Vaknin-Dembinsky, Adi ; Khoury, Salim ; Abramsky, Oded ; Atlan, Henri ; Cohen, Irun R. ; Abulafia-Lapid, Rivka. / T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients : A Randomized, Double-Blind Clinical Trial. In: PLoS One. 2012 ; Vol. 7, No. 12.
@article{9dcd8d3aedd44f62a3ae46a450a05268,
title = "T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial",
abstract = "Background: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. Aim: To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial. Methodology: Twenty-six patients with relapsing-progressive MS were enrolled in the study (mean age: 39±9.8 years; mean EDSS: 4.4±1.7). T-cell lines reactive to 9 different peptides of the myelin antigens, MBP, MOG and PLP were raised from the patients' peripheral blood. The patients were randomized into two groups: 19 were treated with TCV (four subcutaneous injections of 10-30×106 T-cells, attenuated by irradiation, on days 1, 30, 90 and 180) and 7 patients were treated with sham injections. Twenty-four patients (17 in the TCV group and 7 in the placebo) were eligible for per-protocol analysis. Results: At one year following the inclusion, an increase in the EDSS (+0.50) and an increase in 10-meter walking time (+0.18 sec), were observed in the placebo group; in the TCV group there was a decrease in the EDSS (-0.44; p",
author = "Dimitrios Karussis and Hagai Shor and Julia Yachnin and Naama Lanxner and Merav Amiel and Keren Baruch and Yael Keren-Zur and Ofra Haviv and Massimo Filippi and Panayiota Petrou and Shalom Hajag and Urania Vourka-Karussis and Adi Vaknin-Dembinsky and Salim Khoury and Oded Abramsky and Henri Atlan and Cohen, {Irun R.} and Rivka Abulafia-Lapid",
year = "2012",
month = "12",
day = "14",
doi = "10.1371/journal.pone.0050478",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients

T2 - A Randomized, Double-Blind Clinical Trial

AU - Karussis, Dimitrios

AU - Shor, Hagai

AU - Yachnin, Julia

AU - Lanxner, Naama

AU - Amiel, Merav

AU - Baruch, Keren

AU - Keren-Zur, Yael

AU - Haviv, Ofra

AU - Filippi, Massimo

AU - Petrou, Panayiota

AU - Hajag, Shalom

AU - Vourka-Karussis, Urania

AU - Vaknin-Dembinsky, Adi

AU - Khoury, Salim

AU - Abramsky, Oded

AU - Atlan, Henri

AU - Cohen, Irun R.

AU - Abulafia-Lapid, Rivka

PY - 2012/12/14

Y1 - 2012/12/14

N2 - Background: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. Aim: To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial. Methodology: Twenty-six patients with relapsing-progressive MS were enrolled in the study (mean age: 39±9.8 years; mean EDSS: 4.4±1.7). T-cell lines reactive to 9 different peptides of the myelin antigens, MBP, MOG and PLP were raised from the patients' peripheral blood. The patients were randomized into two groups: 19 were treated with TCV (four subcutaneous injections of 10-30×106 T-cells, attenuated by irradiation, on days 1, 30, 90 and 180) and 7 patients were treated with sham injections. Twenty-four patients (17 in the TCV group and 7 in the placebo) were eligible for per-protocol analysis. Results: At one year following the inclusion, an increase in the EDSS (+0.50) and an increase in 10-meter walking time (+0.18 sec), were observed in the placebo group; in the TCV group there was a decrease in the EDSS (-0.44; p

AB - Background: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. Aim: To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial. Methodology: Twenty-six patients with relapsing-progressive MS were enrolled in the study (mean age: 39±9.8 years; mean EDSS: 4.4±1.7). T-cell lines reactive to 9 different peptides of the myelin antigens, MBP, MOG and PLP were raised from the patients' peripheral blood. The patients were randomized into two groups: 19 were treated with TCV (four subcutaneous injections of 10-30×106 T-cells, attenuated by irradiation, on days 1, 30, 90 and 180) and 7 patients were treated with sham injections. Twenty-four patients (17 in the TCV group and 7 in the placebo) were eligible for per-protocol analysis. Results: At one year following the inclusion, an increase in the EDSS (+0.50) and an increase in 10-meter walking time (+0.18 sec), were observed in the placebo group; in the TCV group there was a decrease in the EDSS (-0.44; p

UR - http://www.scopus.com/inward/record.url?scp=84871265763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871265763&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0050478

DO - 10.1371/journal.pone.0050478

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e50478

ER -